Reunion Neuroscience

YTD

ALL

Why Robinhood?

You can watch REUN and buy or sell other stocks, ETFs, and their options commission-free!

About REUN

Reunion Neuroscience, Inc. engages in operating the drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds.

CEO

Gregory T. Mayes, III

CEOGregory T. Mayes, III

Employees

—

Employees—

Headquarters

Toronto, Ontario

HeadquartersToronto, Ontario

Founded

2020

Founded2020

Employees

—

Employees—

REUN Key Statistics

Market cap

13.12M

Market cap13.12M

Price-Earnings ratio

-0.35

Price-Earnings ratio-0.35

Dividend yield

—

Dividend yield—

Average volume

30.83K

Average volume30.83K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$22.00

52 Week high$22.00

52 Week low

$0.6303

52 Week low$0.6303

People also own

Based on the portfolios of people who own REUN. This list is generated using Robinhood data, and it’s not a recommendation.

Mind Medicine (MindMed)